Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
Ludwig Kappos(University Hospital of Basel), Till Sprenger(University of Basel), Magdalena Pirozek-Lawniczek(Janssen (Switzerland)), Fred Lublin(Icahn School of Medicine at Mount Sinai), Reinhard Hohlfeld(Munich Cluster for Systems Neurology), Robert J. Fox(Cleveland Clinic), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Hilke Kracker(Janssen (Switzerland)), Philippe Linscheid(Janssen (Switzerland)), Daniele D’Ambrosio(Actelion (Switzerland)), Eva Havrdová(Charles University), Michel Burcklen(Janssen (Switzerland)), Carlo Pozzilli(Sapienza University of Rome), Mark S. Freedman, Bryan T. Hennessy(Royal College of Surgeons in Ireland), Tatiana Scherz(Janssen (Switzerland)), Andrea Vaclavkova(Janssen (Switzerland))
Cited by 218
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k